NCT05913232View on ClinicalTrials.gov

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

August 28, 2023

Primary Completion Date

August 29, 2024

Study Completion Date

August 29, 2024

Conditions
Glaucoma Open-Angle PrimaryOcular Hypertension
Interventions
DRUG

H-1337 0.6%

ophthalmic solution

DRUG

H-1337 1.0%

ophthalmic solution

DRUG

H-1337 Placebo

ophthalmic solution

DRUG

Timolol 0.5%

ophthalmic solution

Trial Locations (9)

14618

Rochester Ophthalmological Group, PC, Rochester

24011

Vistar Eye Center, Roanoke

30076

Coastal Research Associates, LLC, Roswell

31701

Dixon Eye Care, Albany

33773

Shettle Eye Research, Inc., Largo

33805

Central Florida Eye Associates, Lakeland

37803

University Eye Specialists, Maryville

80907

Skyline Vision Clinic and Laser Center, Colorado Springs

91204

Global Research Management, Glendale

All Listed Sponsors
lead

D. Western Therapeutics Institute, Inc.

INDUSTRY

NCT05913232 - Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter